{"product_id":"hepalink-business-model-canvas","title":"Shenzhen Hepalink Pharmaceutical Group Co. Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepalink's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic engine behind Shenzhen Hepalink Pharmaceutical Group Co.'s success with our comprehensive Business Model Canvas. This detailed breakdown illuminates their key partners, customer relationships, and value propositions in the competitive pharmaceutical landscape. Understand how they leverage their core activities and revenue streams to drive growth and innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group actively engages in strategic pharmaceutical collaborations, partnering with other industry players for co-development, distribution, and commercialization. These alliances are vital for expanding market reach and capitalizing on complementary expertise across diverse therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Hepalink's commitment to these partnerships was evident in its ongoing efforts to accelerate the development and market entry of innovative drugs and biosimilars. For instance, its collaborations aim to streamline clinical trials and regulatory approvals, a critical factor in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group's success hinges on its raw material suppliers, especially for crude heparin, the foundational component of its products.  Maintaining a consistent, high-quality supply is paramount for production continuity and adherence to stringent pharmaceutical standards.  In 2023, Hepalink continued to emphasize long-term relationships and a diversified sourcing approach to buffer against potential disruptions in this critical supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations (CDMO) Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group's CDMO clients, primarily biopharmaceutical companies worldwide, are crucial partners. Through subsidiaries like Cytovance and SPL, Hepalink offers extensive manufacturing and development services, making these clients the backbone of its CDMO revenue stream.\u003c\/p\u003e\n\u003cp\u003eThese relationships are fundamental for Hepalink, as they directly fuel growth by utilizing the company's advanced manufacturing infrastructure and specialized expertise. The success of Hepalink's CDMO segment is intrinsically linked to the success and demand from these client companies.\u003c\/p\u003e\n\u003cp\u003eCultivating enduring partnerships with CDMO clients is paramount for securing consistent business and enhancing Hepalink's standing in the competitive biopharmaceutical outsourcing market. For instance, in 2023, Hepalink's CDMO segment demonstrated robust performance, contributing significantly to the group's overall financial results, underscoring the importance of these client relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group Co. relies heavily on collaborations with universities, research centers, and biotech firms. These partnerships are crucial for its strategic push into innovative drugs and biosimilars, allowing Hepalink to tap into cutting-edge research and novel technologies.\u003c\/p\u003e\n\u003cp\u003eThese alliances are instrumental in accelerating preclinical and clinical development phases. For instance, in 2024, Hepalink announced a significant collaboration with a leading academic institution to explore novel therapeutic targets for rare diseases, underscoring the importance of these R\u0026amp;D partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUniversity Collaborations:\u003c\/strong\u003e Access to academic expertise and early-stage research findings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResearch Center Alliances:\u003c\/strong\u003e Joint projects for specialized research and validation of new drug candidates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiotech Firm Partnerships:\u003c\/strong\u003e Co-development of innovative therapies and biosimilars, sharing risks and rewards.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSuch strategic alliances not only bolster Hepalink's intellectual property portfolio but also significantly contribute to its future product pipeline, ensuring sustained growth and competitiveness in the pharmaceutical market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Sales Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group leverages a robust global distribution and sales network, partnering with specialized distributors and sales agencies worldwide. These collaborations are crucial for ensuring broad market penetration of its heparin products and other pharmaceutical offerings.\u003c\/p\u003e\n\u003cp\u003eThese key partners bring invaluable localized market intelligence, navigate complex regional regulatory landscapes, and possess established sales channels. This strategic approach allows Hepalink to effectively reach diverse customer segments across major markets including Europe, the United States, and its home market in China, as well as other international territories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Reach:\u003c\/strong\u003e Hepalink's network spans over 100 countries, facilitating access to critical pharmaceutical markets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expertise:\u003c\/strong\u003e Partners provide deep understanding of local healthcare systems and purchasing behaviors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Navigation:\u003c\/strong\u003e Local partners assist in complying with diverse international drug approval and distribution regulations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Channel Access:\u003c\/strong\u003e Established relationships with healthcare providers and pharmacies ensure efficient product placement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoundational Partnerships Drive Innovation and Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group's key partnerships are foundational to its business model, particularly in R\u0026amp;D and market access. Collaborations with universities, research centers, and biotech firms are critical for driving innovation in new drugs and biosimilars, as seen in their 2024 alliance with a leading academic institution for rare disease research.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Hepalink relies on a global network of distributors and sales agencies to ensure its products reach diverse markets. These partners provide essential local market intelligence and navigate complex regulatory environments, facilitating access to over 100 countries.\u003c\/p\u003e\n\u003cp\u003eThe company also cultivates strong relationships with its CDMO clients, which are vital for its manufacturing services segment. These clients, primarily biopharmaceutical companies, directly contribute to Hepalink's revenue streams by utilizing its advanced manufacturing capabilities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eKey Role\u003c\/th\u003e\n\u003cth\u003e2024 Focus\/Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/Research Institutions\u003c\/td\u003e\n\u003ctd\u003eEarly-stage research, novel target identification\u003c\/td\u003e\n\u003ctd\u003eExploring rare disease therapeutics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech Firms\u003c\/td\u003e\n\u003ctd\u003eCo-development of innovative therapies\/biosimilars\u003c\/td\u003e\n\u003ctd\u003eAccelerating pipeline development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Clients\u003c\/td\u003e\n\u003ctd\u003eUtilizing manufacturing services, revenue generation\u003c\/td\u003e\n\u003ctd\u003eDriving growth in outsourcing market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\/Sales Agencies\u003c\/td\u003e\n\u003ctd\u003eMarket access, regulatory navigation, sales\u003c\/td\u003e\n\u003ctd\u003eExpanding global reach across 100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis Business Model Canvas for Shenzhen Hepalink Pharmaceutical Group Co. outlines a strategy focused on heparin-based products and biopharmaceuticals, detailing customer segments like hospitals and pharmaceutical companies, and value propositions centered on high-quality, innovative medical solutions.\u003c\/p\u003e\n\u003cp\u003eIt covers key resources such as R\u0026amp;D capabilities and manufacturing facilities, alongside channels like direct sales and partnerships, to achieve its growth objectives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group Co.'s Business Model Canvas acts as a pain point reliever by streamlining complex pharmaceutical supply chains and ensuring reliable access to critical heparin products.\u003c\/p\u003e\n\u003cp\u003eThis one-page snapshot effectively addresses the pain of drug shortages and inconsistent quality in the pharmaceutical market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group Co. is heavily invested in expanding its pharmaceutical portfolio through rigorous research and development. This includes developing novel therapeutics and high-quality biosimilars, aiming to diversify beyond its established heparin products.\u003c\/p\u003e\n\u003cp\u003eThe company's R\u0026amp;D efforts encompass the entire drug development lifecycle, from early-stage preclinical investigations to extensive clinical trials. Notable examples include advancements in H1710 injection and Oregovomab, showcasing their commitment to bringing new treatments to market. This pipeline is vital for sustained growth and maintaining a competitive edge in the dynamic biopharmaceutical landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing of Active Pharmaceutical Ingredients (APIs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group's core activity is the large-scale manufacturing of heparin sodium Active Pharmaceutical Ingredients (APIs). This process is intricate, involving sophisticated chemical and biological techniques, and demanding rigorous quality assurance to meet international Good Manufacturing Practice (GMP) standards. Hepalink operates multiple advanced facilities in both China and the United States to ensure this critical component is produced efficiently and compliantly.\u003c\/p\u003e\n\u003cp\u003eThis robust API production capability is fundamental to Hepalink's business, providing a consistent and high-quality supply of heparin sodium. This not only supports the company's own downstream manufacturing of finished pharmaceutical products but also serves a significant external market, supplying APIs to other pharmaceutical companies globally. In 2024, Hepalink continued to be a major global supplier of heparin APIs, contributing significantly to the supply chain of anticoagulant medications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduction of Finished Dose Pharmaceutical Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHepalink's core activity involves the manufacturing of finished dose pharmaceutical products, primarily low molecular weight heparin (LMWH) preparations. This encompasses crucial steps like formulation, sterile filling, and final packaging, all conducted under strict Good Manufacturing Practices (GMP) to ensure patient safety and product efficacy.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Hepalink's finished drug business saw significant growth, contributing approximately 3.6 billion RMB to its total revenue. This segment is vital for the company's strategy to move up the value chain, transforming raw heparin into readily usable medications.\u003c\/p\u003e\n\u003cp\u003eThe production of these finished doses allows Hepalink to directly serve patients and healthcare providers, capturing a larger portion of the profit margin compared to simply supplying raw heparin. This also facilitates diversification beyond LMWH into other therapeutic areas, enhancing market resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organization (CDMO) Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHepalink's key activities include a growing focus on Contract Development and Manufacturing Organization (CDMO) services. This segment supports the development and production of biopharmaceutical products, encompassing areas like mammalian cell culture, microbial fermentation, cell and gene therapies, and mRNA technologies.\u003c\/p\u003e\n\u003cp\u003eThese CDMO services leverage Hepalink's sophisticated manufacturing infrastructure and deep scientific expertise. By offering these capabilities to other biopharmaceutical companies, Hepalink diversifies its revenue streams and maximizes the utilization of its advanced production facilities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiopharmaceutical Manufacturing:\u003c\/strong\u003e Offering CDMO services for mammalian cell culture, microbial, cell and gene therapy, and mRNA products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdvanced Capabilities:\u003c\/strong\u003e Utilizing cutting-edge technology and scientific know-how to support clients' drug development pipelines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Diversification:\u003c\/strong\u003e Expanding CDMO services contributes to a broader and more resilient revenue base for Hepalink.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfrastructure Optimization:\u003c\/strong\u003e Maximizing the efficiency and return on investment for its manufacturing assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShenzhen Hepalink Pharmaceutical Group Co. actively pursues global sales and marketing for its heparin-based Active Pharmaceutical Ingredients (APIs), finished dosage forms, and Contract Development and Manufacturing Organization (CDMO) services.  This strategy targets key international markets, aiming to broaden its reach and customer base.\u003c\/p\u003e\n\u003cp\u003eThe company establishes and manages its own sales teams in crucial regions such as Europe and the United States. This direct approach ensures better market penetration and customer relationship management.  Securing necessary market entry licenses is a critical step in this process, facilitating legal and compliant operations in new territories.\u003c\/p\u003e\n\u003cp\u003eHepalink also engages with national centralized procurement platforms, a vital channel for accessing large-scale government contracts, particularly in markets like China.  In 2024, Hepalink reported significant international sales contributions, with its overseas operations playing a crucial role in its overall revenue growth.  For instance, its US subsidiary, Scientific Protein Laboratories (SPL), continued to be a major supplier of heparin APIs globally.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Reach\u003c\/strong\u003e: Hepalink's sales and marketing efforts span across Europe, the US, and other international markets for its heparin APIs, finished drugs, and CDMO services.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect Sales Force\u003c\/strong\u003e: The company operates self-managed sales teams in key regions like Europe and the US to enhance market presence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access\u003c\/strong\u003e: Obtaining market entry licenses and participating in national centralized procurement platforms are key activities for expanding sales.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Driver\u003c\/strong\u003e: Effective global sales and marketing are fundamental to driving revenue and increasing Hepalink's market share in the pharmaceutical sector.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Biopharma: Manufacturing, Innovation \u0026amp; CDMO Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey activities for Shenzhen Hepalink Pharmaceutical Group Co. involve the robust manufacturing of heparin sodium Active Pharmaceutical Ingredients (APIs) and finished low molecular weight heparin (LMWH) preparations. These core operations are supported by significant investments in research and development for novel therapeutics and biosimilars, aiming to diversify its product portfolio beyond heparin. Furthermore, Hepalink actively expands its Contract Development and Manufacturing Organization (CDMO) services, leveraging its advanced infrastructure for biopharmaceutical production.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2023\/2024 Relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI Manufacturing\u003c\/td\u003e\n\u003ctd\u003eLarge-scale production of heparin sodium APIs adhering to international GMP standards.\u003c\/td\u003e\n\u003ctd\u003eHepalink remained a major global supplier of heparin APIs in 2024, with its US subsidiary, Scientific Protein Laboratories (SPL), playing a critical role.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinished Drug Production\u003c\/td\u003e\n\u003ctd\u003eFormulation, sterile filling, and packaging of LMWH preparations.\u003c\/td\u003e\n\u003ctd\u003eThe finished drug business contributed approximately 3.6 billion RMB to total revenue in 2023, highlighting its importance in moving up the value chain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDeveloping novel therapeutics and biosimilars, including H1710 injection and Oregovomab.\u003c\/td\u003e\n\u003ctd\u003eContinuous R\u0026amp;D is vital for sustained growth and maintaining a competitive edge in the biopharmaceutical sector.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Services\u003c\/td\u003e\n\u003ctd\u003eOffering services for mammalian cell culture, microbial fermentation, cell \u0026amp; gene therapy, and mRNA products.\u003c\/td\u003e\n\u003ctd\u003eDiversifies revenue streams and maximizes the utilization of advanced production facilities by supporting other biopharmaceutical companies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas for Shenzhen Hepalink Pharmaceutical Group Co. that you are previewing is the exact document you will receive upon purchase. This comprehensive canvas outlines Hepalink's core business activities, customer segments, value propositions, and revenue streams, providing a clear strategic overview. You'll gain immediate access to this fully detailed, ready-to-use document, enabling you to understand and apply its insights directly to your own business analysis or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611306443129,"sku":"hepalink-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hepalink-business-model-canvas.png?v=1754754960","url":"https:\/\/matrixbcg.com\/products\/hepalink-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}